Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)

NCT01852071 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT01852071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01852071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
Lead sponsor
University of California, Los Angeles
Phase
Phase 1/2
Overall status
Completed
Start date
August 2, 2013
Completion date
August 27, 2018
Enrollment
46 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ada-scid